Innovative Partnership Enhances Cancer Care Through Liquid Biopsy
A.D.A.M. Innovations and SOPHiA GENETICS Collaborate to Elevate Cancer Diagnostics
In a groundbreaking partnership, A.D.A.M. Innovations, a premier genetic testing firm in Japan, has joined forces with SOPHiA GENETICS, an innovative AI technology company, to revolutionize liquid biopsy testing and companion diagnostics for precision oncology.
With a significant presence in the market, A.D.A.M. Innovations has been delivering exceptional genetic testing services for over twenty years, completing more than 2.8 million tests to date. This collaboration aims to leverage the advanced capabilities of the SOPHiA DDM™ Platform, enhancing personalized cancer testing throughout Japan.
Bridging Technology with Healthcare
Central to this partnership is the launch of the liquid biopsy application utilizing MSK-ACCESS® powered by SOPHiA DDM™. This state-of-the-art test employs advanced AI techniques to detect actionable genomic alterations from just a single blood draw. By analyzing circulating tumor DNA (ctDNA), it offers a minimally invasive method to improve patient outcomes. Additionally, the test's matched tumor-normal approach efficiently boosts accuracy, minimizing instances of false positives.
Importantly, by processing samples locally, A.D.A.M. Innovations aims to greatly reduce testing time and costs for patients, effectively supporting local cancer research initiatives.
Developing Cutting-Edge Companion Diagnostics
The alliance also includes plans to create a liquid biopsy companion diagnostic (CDx) test catered specifically for the Japanese healthcare landscape. This endeavor seeks to expand access to high-quality tumor profiling, ensuring more patients benefit from personalized healthcare solutions. Moreover, pharmaceutical partners will gain access to a robust new tool designed to expedite drug development and secure market access in Japan.
Throughout the collaboration, A.D.A.M. Innovations will utilize its vast clinical and regulatory expertise to facilitate necessary regulatory submissions, enhancing the efficiency of the development process.
Impact on Patients and Healthcare Providers
“Bringing precision oncology to patients in Japan marks a significant achievement for both companies,” stated Ross Muken, President of SOPHiA GENETICS. The synergy between A.D.A.M. Innovations’ local expertise and the innovative capabilities of the SOPHiA DDM™ Platform promises to transform the landscape of data-driven medicine, propelling advancements in clinical research and tailored oncology care.
Michel Mommejat, President of A.D.A.M. Innovations, remarked, “Having supported medical institutions with advanced genomic testing for years, we are excited about the potential of our partnership with SOPHiA GENETICS. By facilitating local testing, we can ensure quicker results, lower costs, and improved patient care while contributing to international CDx deployments.”
Looking Ahead
The collaboration was prominently announced at the European Society for Medical Oncology (ESMO) Congress 2025, highlighting the shared commitment of both organizations to foster data-driven, liquid biopsy solutions for cancer treatment in Japan. Interested individuals can engage with both companies at ESMO booth #2039 at the upcoming event.
About the Companies
SOPHiA GENETICS (Nasdaq: SOPH) is renowned globally for its mission to expand access to data-driven medicine, harnessing AI technology for improved healthcare delivery to patients facing cancer and rare disorders. The SOPHiA DDM™ Platform stands out by analyzing complex genomic data, delivering actionable insights to a vast network of medical and laboratory institutions.
A.D.A.M. Innovations, established in Tokyo in 2004, specializes in genomics and innovative health solutions. The company conducts extensive research and maintains the largest genomic database of Japan's population, having developed multiple technologies for clinical diagnostics, consumer genetics, and AI-driven research and development platforms. The company will transition to A.D.A.M. Innovations Co. effective November 1, 2025.
Frequently Asked Questions
What is the main goal of the partnership between A.D.A.M. Innovations and SOPHiA GENETICS?
The primary aim is to enhance liquid biopsy testing and companion diagnostics for precision oncology in Japan, making these advanced healthcare solutions more accessible.
What technology is being utilized in the liquid biopsy tests?
The partnership will utilize the SOPHiA DDM™ Platform to provide advanced genomic analysis capabilities for liquid biopsy testing.
How will the partnership benefit patients in Japan?
This collaboration aims to reduce testing turnaround times and costs for patients, providing quicker access to crucial cancer diagnostics.
What are liquid biopsy companion diagnostics?
Companion diagnostics are tests designed to provide essential information to optimize treatment decisions for patients, particularly in cancer therapy.
How has A.D.A.M. Innovations contributed to genetic testing in Japan?
A.D.A.M. Innovations has been a leader in genetic testing in Japan for over 20 years, having conducted over 2.8 million tests to support patients and healthcare providers.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.